Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
A prescription drug's label AE section is almost entirely based on clinicians' impression of patients' symptoms, not the patients' own reports.
More Sarcoma Information
This fact sheet educates patients on how to properly describe the details of their metastatic breast cancer pain to their oncologist.
A fact sheet to review the different types of test used to detect colon cancer and polyps.
This fact sheet offers tips for patients to help keep their memory sharp during cancer treatment.
This fact sheet reviews information on the diagnosis, treatment, grade, and management of follicular lymphoma cancer.
This fact sheet offers tips to help patients with acute chronic myelogenous leukemia overcome challenges to adhering to treatment regimens.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- FDA Grants Breakthrough Therapy Designation to Cabozantinib for Renal Cell Carcinoma
- In Fit Patients With NSCLC, Erlotinib Not Recommended
- New Hormonal Agents for Prostate Cancer May Increase Risk of Cardiotoxicity
- Dasatinib-induced Pulmonary Hypertension in Patients With Leukemia
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology
- A Decade of Dramatic Change in the Treatment of Prostate Cancer
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- In Heavily Pretreated Refractory Myeloma, Daratumumab May Be Safe, Effective
- In Locoregionally Advanced Oral Cavity Cancer, Preop Induction Chemo May Not Improve Outcomes
- Patients With Solid Tumors Face Risk for Critical Illness
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|